Novartis has agreed to pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager designed to reset B cells by in vivo production of the engager. The agreement, reported via deal coverage, values the partnership at up to ~$7.8 billion in potential development, regulatory, and commercial milestones depending on options exercised. The transaction follows a pattern of large pharma using China-based platforms to replenish early pipeline assets. Abogen retains non-exclusive rights to its broader RNA platform development outside the licensed programs, with the company expected to advance ABO2203 toward later-stage trials under Novartis oversight. For investors and developers, the structure underscores how mRNA-encoded “engager” programs are shifting from concept to scaled partnering, with attention on the ability to manage target engagement kinetics while maintaining safety in autoimmune indications.